Q2 EPS Estimates for Myomo Cut by Ascendiant Capital Markets

Myomo, Inc. (NYSEAMERICAN:MYO) – Research analysts at Ascendiant Capital Markets dropped their Q2 2026 earnings per share estimates for shares of Myomo in a research note issued to investors on Saturday, June 6th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings of ($0.11) per share for the quarter, down from their prior estimate of ($0.10). Ascendiant Capital Markets currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.28) per share. Ascendiant Capital Markets also issued estimates for Myomo’s Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.03) EPS.

Separately, Craig Hallum reissued a “buy” rating on shares of Myomo in a research note on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $7.67.

Myomo Trading Up 17.6%

NYSEAMERICAN MYO opened at $1.54 on Thursday. Myomo has a 1-year low of $0.61 and a 1-year high of $2.95. The company has a current ratio of 2.73, a quick ratio of 2.36 and a debt-to-equity ratio of 1.21. The stock has a 50-day moving average of $0.90 and a 200-day moving average of $0.88. The firm has a market cap of $59.51 million, a PE ratio of -4.28 and a beta of 1.47.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its position in Myomo by 93.6% during the 3rd quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock valued at $27,000 after purchasing an additional 14,705 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Myomo by 103.1% during the 4th quarter. Wells Fargo & Company MN now owns 38,707 shares of the company’s stock worth $35,000 after acquiring an additional 19,646 shares during the period. Invesco Ltd. purchased a new position in shares of Myomo during the 2nd quarter worth approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Myomo during the 2nd quarter worth approximately $38,000. Finally, Jane Street Group LLC purchased a new position in shares of Myomo during the 4th quarter worth approximately $64,000. Institutional investors own 44.99% of the company’s stock.

Insider Buying and Selling

In other Myomo news, Director Joseph M. Jr. Manko purchased 170,830 shares of the stock in a transaction on Thursday, May 14th. The stock was acquired at an average price of $0.86 per share, with a total value of $146,913.80. Following the transaction, the director directly owned 2,279,408 shares of the company’s stock, valued at approximately $1,960,290.88. This trade represents a 8.10% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Thomas F. Kirk purchased 72,000 shares of the stock in a transaction on Friday, March 13th. The shares were acquired at an average cost of $0.71 per share, with a total value of $51,120.00. Following the transaction, the director directly owned 553,857 shares in the company, valued at $393,238.47. The trade was a 14.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 433,205 shares of company stock valued at $382,868 in the last ninety days. 12.14% of the stock is currently owned by corporate insiders.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.